X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-03-20 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $7.76 | -2,193 | 65,360 | -3% | -$17,018 | ||||||
2023-03-20 | VYGR | Swartz Robin | COO | S - Sale | $7.76 | -3,654 | 72,876 | -5% | -$28,355 | ||||||
2023-03-20 | VYGR | Hesslein Robert W. | SVP, GC | S - Sale | $7.76 | -4,410 | 102,200 | -4% | -$34,222 | ||||||
2023-03-15 | VYGR | Swartz Robin | COO | S - Sale | $8.20 | -15,373 | 76,530 | -17% | -$126,059 | ||||||
2023-02-23 | VYGR | Neurocrine Biosciences Inc | 10% | P - Purchase | $8.88 | +4,395,588 | 8,575,316 | +105% | +$39,032,821 | ||||||
2023-02-17 | VYGR | Hesslein Robert W. | SVP, GC | S - Sale | $7.45 | -3,297 | 106,610 | -3% | -$24,563 | ||||||
| D | 2023-02-17 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale+OE | $7.45 | -738 | 67,553 | -1% | -$5,498 | |||||
2023-02-13 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $7.67 | -797 | 34,291 | -2% | -$6,113 | ||||||
2023-02-13 | VYGR | Hesslein Robert W. | SVP, GC | S - Sale | $7.67 | -2,868 | 109,907 | -3% | -$21,998 | ||||||
| M | 2023-01-30 | VYGR | Third Rock Ventures Iii, L.P. | 10% | S - Sale | $9.23 | -388,642 | 4,721,992 | -8% | -$3,587,443 | |||||
2023-01-27 | VYGR | Third Rock Ventures Iii, L.P. | 10% | S - Sale | $9.02 | -50,000 | 5,110,634 | -1% | -$451,000 | ||||||
| M | 2023-01-24 | VYGR | Third Rock Ventures Iii, L.P. | 10% | S - Sale | $9.25 | -150,000 | 5,160,634 | -3% | -$1,388,000 | |||||
| M | 2023-01-20 | VYGR | Third Rock Ventures Iii, L.P. | 10% | S - Sale | $9.12 | -155,000 | 5,310,634 | -3% | -$1,413,300 | |||||
2023-01-17 | VYGR | Hesslein Robert W. | SVP, GC | S - Sale | $9.85 | -2,188 | 112,775 | -2% | -$21,549 | ||||||
2023-01-17 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $9.85 | -1,106 | 35,088 | -3% | -$10,892 | ||||||
2023-01-17 | VYGR | Swartz Robin | COO | S - Sale | $9.85 | -2,188 | 51,903 | -4% | -$21,549 | ||||||
| M | 2023-01-09 | VYGR | Ecor1 Capital, LLC | 10% | S - Sale | $7.91 | -902,400 | 3,851,507 | -19% | -$7,142,343 | |||||
2023-01-06 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $6.41 | -388 | 36,194 | -1% | -$2,487 | ||||||
| M | 2022-08-24 | VYGR | Third Rock Ventures Iii, L.P. | 10% | S - Sale | $6.16 | -349,972 | 5,465,634 | -6% | -$2,157,329 | |||||
2022-08-16 | VYGR | Third Rock Ventures Iii, L.P. | 10% | S - Sale | $6.04 | -128,456 | 5,815,606 | -2% | -$775,874 | ||||||
| M | 2022-08-12 | VYGR | Third Rock Ventures Iii, L.P. | 10% | S - Sale | $6.10 | -483,815 | 5,944,062 | -8% | -$2,950,083 | |||||
2022-07-14 | VYGR | Pierce Glenn | Dir | S - Sale | $6.70 | -9,512 | 21,788 | -30% | -$63,730 | ||||||
2022-07-14 | VYGR | Higgins Michael J | Dir | S - Sale | $6.70 | -13,891 | 31,314 | -31% | -$93,070 | ||||||
| M | 2022-06-21 | VYGR | Ecor1 Capital, LLC | 10% | P - Purchase | $5.58 | +477,400 | 4,753,907 | +11% | +$2,662,047 | |||||
2022-04-04 | VYGR | Swartz Robin | COO | S - Sale | $8.25 | -1,527 | 52,060 | -3% | -$12,598 | ||||||
2022-04-04 | VYGR | Hesslein Robert W. | SVP, GC | S - Sale | $8.25 | -2,786 | 114,963 | -2% | -$22,985 | ||||||
2022-03-21 | VYGR | Swartz Robin | COO | S - Sale | $8.29 | -4,413 | 53,587 | -8% | -$36,604 | ||||||
2022-03-21 | VYGR | Hesslein Robert W. | SVP, GC | S - Sale | $8.29 | -4,955 | 117,749 | -4% | -$41,100 | ||||||
2022-03-21 | VYGR | Burek Julie | VP, Finance | S - Sale | $8.29 | -2,649 | 52,458 | -5% | -$21,972 | ||||||
2022-02-17 | VYGR | Hesslein Robert W. | SVP, GC | S - Sale | $3.55 | -4,100 | 122,704 | -3% | -$14,555 | ||||||
2022-02-17 | VYGR | Burek Julie | VP, Finance | S - Sale | $3.55 | -789 | 55,107 | -1% | -$2,801 | ||||||
2022-02-11 | VYGR | Hesslein Robert W. | SVP, GC | S - Sale | $3.36 | -3,252 | 126,804 | -3% | -$10,927 | ||||||
2022-02-11 | VYGR | Burek Julie | VP, Finance | S - Sale | $3.36 | -361 | 55,896 | -1% | -$1,213 | ||||||
| M | 2022-01-03 | VYGR | Burek Julie | VP, Finance | S - Sale | $2.85 | -3,328 | 46,257 | -7% | -$9,479 | |||||
2021-05-21 | VYGR | Khwaja Omar | See Remarks | S - Sale | $4.03 | -3,516 | 120,509 | -3% | -$14,169 | ||||||
2021-04-05 | VYGR | Hesslein Robert W. | SVP, GC | S - Sale | $4.95 | -3,292 | 110,056 | -3% | -$16,295 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |